{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T11:19:55Z","timestamp":1774696795944,"version":"3.50.1"},"reference-count":19,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The coronavirus disease 2019 (COVID-19) pandemic introduced unprecedented disruptions to health care delivery, compelling rapid adaptations in anticoagulation management. Direct oral anticoagulants (DOACs), already displacing warfarin due to their convenience and reduced monitoring requirements, appeared well-positioned for broader adoption during pandemic-induced lockdowns. This commentary examines whether the pandemic catalyzed a meaningful shift in anticoagulant prescribing patterns from vitamin K antagonists (VKAs) to DOACs, drawing on data from the United Kingdom, Australia, the United States, Europe, and Asia. In the United Kingdom, national guidance led to an abrupt and large-scale switch to DOACs, with sustained changes postpandemic. In contrast, Australia and the United States exhibited continuity in preexisting trends, with modest, transient shifts that did not persist. Asian and European data revealed a gradual trajectory toward DOACs, likely driven by long-term policy and infrastructure rather than acute pandemic pressures. While no universal transformation occurred, the pandemic accentuated existing preferences and exposed system-level vulnerabilities in warfarin monitoring. The global experience suggests that the COVID-19 crisis served as a selective accelerant of DOACs adoption, where health care systems and policies facilitated change. As health systems prepare for future disruptions, equitable access to DOACs and investment in remote care infrastructure will be essential to ensuring continuity and safety in anticoagulation therapy.<\/jats:p>","DOI":"10.1055\/a-2667-6770","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T22:45:06Z","timestamp":1753742706000},"page":"139-143","source":"Crossref","is-referenced-by-count":2,"title":["COVID-19 and Anticoagulant Use: Did the Pandemic Push DOACs Ahead of Warfarin?"],"prefix":"10.1055","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4367-5182","authenticated-orcid":false,"given":"Bingwen Eugene","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Haematology, Tan Tock Seng Hospital, Singapore"},{"name":"Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore"},{"name":"Department of Laboratory Medicine, Khoo Teck Puat Hospital, Singapore"},{"name":"Yong Loo Lin School of Medicine, National University of Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4995-7587","authenticated-orcid":false,"given":"Jia Hui Melissa","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Sciences, Faculty of Science, National University of Singapore, Singapore"},{"name":"Department of Pharmacy, Sengkang General Hospital, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doreen Su-Yin","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Sciences, Faculty of Science, National University of Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"issue":"08","key":"ref1","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.3390\/jcm14082591","article-title":"Oral anticoagulation therapy: An update on usage and costs in the endemic COVID-19 era","volume":"14","author":"E J Favaloro","year":"2025","journal-title":"J Clin Med"},{"issue":"05","key":"ref3","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s11739-020-02391-3","article-title":"Managing anticoagulation in the COVID-19 era between lockdown and reopening phases","volume":"15","author":"D Poli","year":"2020","journal-title":"Intern Emerg Med"},{"issue":"01","key":"ref4","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41591-022-02158-7","article-title":"The impact of the COVID-19 pandemic on cardiovascular disease prevention and management","volume":"29","author":"C E Dale","year":"2023","journal-title":"Nat Med"},{"issue":"03","key":"ref5","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1055\/a-1469-7481","article-title":"Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID-19 vaccination: Guidance statement from the GTH","volume":"41","author":"J Oldenburg","year":"2021","journal-title":"Hamostaseologie"},{"issue":"18","key":"ref6","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMoa2109908","article-title":"Clinical features of vaccine-induced immune thrombocytopenia and thrombosis","volume":"385","author":"S Pavord","year":"2021","journal-title":"N Engl J Med"},{"issue":"07","key":"ref7","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1080\/03007995.2022.2078100","article-title":"Impact of the COVID-19 pandemic on England's national prescriptions of oral vitamin K antagonist (VKA) and direct-acting oral anticoagulants (DOACs): an interrupted time series analysis (January 2019-February 2021)","volume":"38","author":"S Alkhameys","year":"2022","journal-title":"Curr Med Res Opin"},{"issue":"02","key":"ref8","doi-asserted-by":"crossref","first-page":"e001784","DOI":"10.1136\/openhrt-2021-001784","article-title":"OpenSAFELY: impact of national guidance on switching anticoagulant therapy during COVID-19 pandemic","volume":"8","author":"H J Curtis","year":"2021","journal-title":"Open Heart"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.thromres.2020.11.004","article-title":"Switching warfarin patients to a direct oral anticoagulant during the coronavirus disease-19 pandemic","volume":"197","author":"R Patel","year":"2021","journal-title":"Thromb Res"},{"issue":"04","key":"ref10","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/17512433.2025.2473613","article-title":"Impact of COVID-19 pandemic on the prescribing pattern of oral anticoagulants in the English primary care setting: a population-based segmented interrupted time series analysis of over 53 million individuals","volume":"18","author":"A Kurdi","year":"2025","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"12","key":"ref11","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1111\/jth.15881","article-title":"Assessment of immunological anti-platelet factor 4 antibodies for vaccine-induced thrombotic thrombocytopenia (VITT) in a large Australian cohort: A multicenter study comprising 1284 patients","volume":"20","author":"E J Favaloro","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref12","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.pathol.2017.04.011","article-title":"Replacing warfarin therapy with the newer direct oral anticoagulants, or simply a growth in anticoagulation therapy? Implications for pathology testing","volume":"49","author":"E J Favaloro","year":"2017","journal-title":"Pathology"},{"issue":"22","key":"ref13","doi-asserted-by":"crossref","first-page":"e026723","DOI":"10.1161\/JAHA.122.026723","article-title":"Trends in oral anticoagulant use among 436\u2009864 patients with atrial fibrillation in community practice, 2011 to 2020","volume":"11","author":"A M Navar","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"01","key":"ref14","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11239-020-02138-z","article-title":"Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum","volume":"50","author":"G D Barnes","year":"2020","journal-title":"J Thromb Thrombolysis"},{"issue":"24","key":"ref15","doi-asserted-by":"crossref","first-page":"e023235","DOI":"10.1161\/JAHA.121.023235","article-title":"COVID-19 and Anticoagulation for Atrial Fibrillation: An analysis of US Nationwide Pharmacy Claims Data","volume":"10","author":"I Hernandez","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"04","key":"ref16","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/jalm\/jfab025","article-title":"Side-effects of COVID-19 on patient care: An INR story","volume":"6","author":"L N Pearson","year":"2021","journal-title":"J Appl Lab Med"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1093\/ajhp\/zxab332","article-title":"Drive-through point-of-care INR testing: Novel concepts for delivery of care during the COVID-19 pandemic","volume":"79","author":"B Peduzzi","year":"2022","journal-title":"Am J Health Syst Pharm"},{"key":"ref18","first-page":"100396","article-title":"COVID-19 pandemic and trends in clinical outcomes and medication use for patients with established atrial fibrillation: A nationwide analysis of claims data","volume":"42","author":"I Hernandez","year":"2024","journal-title":"Am Heart J Plus"},{"issue":"04","key":"ref19","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1253\/circj.CJ-22-0023","article-title":"10-Year trends of antithrombotic therapy status and outcomes in Japanese atrial fibrillation patients - The Fushimi AF Registry","volume":"86","author":"M Akao","year":"2022","journal-title":"Circ J"},{"issue":"06","key":"ref20","first-page":"e20001","article-title":"Correction to \u2018Initiation of Anticoagulants During the COVID-19 Pandemic in Sweden: An Interrupted Time Series Analysis\u2019","volume":"136","author":"P J Samuelsen","year":"2025","journal-title":"Basic Clin Pharmacol Toxicol"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2667-6770.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T23:36:16Z","timestamp":1768347376000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2667-6770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":19,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2026,1,13]]},"published-print":{"date-parts":[[2026,2]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2667-6770","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7,28]]},"published":{"date-parts":[[2025,7,28]]}}}